The Oley Foundation
The Oley Foundation is a national non-profit organization, founded in 1983. They aim to “enrich the lives of patients dependent on home intravenous nutrition (parenteral) and tube feeding (enteral) through education, advocacy, and networking.” They are a “resource for consumer’s families, clinicians and industry representatives, and other interested parties. The Foundation gives members the tools and confidence they need to manage their complex therapy and enables them to achieve normalcy in their lives.”
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Gastroschisis, Short bowel syndrome, Systemic Scleroderma, Gastroparesis
Celebrate Gastroschisis Awareness Month with Avery’s Angels Foundation
July is Gastroschisis Awareness Month! Thanks to the great work of the Avery’s Angels Gastroschisis Foundation, there are a number of ways and resources to
The FDA Has Just Approved Teduglutide for Children with Short Bowel Syndrome
Short Bowel Syndrome Short bowel syndrome (SBS) is a rare condition which occurs when patients have a large portion of their intestine removed. The surgery
Data From Early Short Bowel Syndrome Trials Presented
According to a story from PR Newswire, the biopharmaceutical company Therachon AG recently issued a presentation of results from the company’s Phase I clinical trial.
Orphan Drug Designation Granted to Therachon’s Drug Apraglutide by FDA for Treatment of Short Bowel Syndrome
A recent article in CheckOrphan reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the synthetic GLP-2 analog apraglutide for the
A New Short Bowel Syndrome Drug is Awaiting Approval
Short bowel syndrome is a malabsorption disorder that causes the body to not get the fluids or nutrients it needs. It can cause dehydration and
New Short Bowel Syndrome Treatment Enters Phase 3 Trial
Zealand Pharma A/S (Zealand) recently announced in a press release the start phase 3 trial for short bowel syndrome treatment. The trial investigates the use
